E3 Ligand-Linker Conjugate 9 is primarily utilized in the field of targeted protein degradation, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). This compound plays a crucial role in linking an E3 ubiquitin ligase ligand to a target protein-binding molecule, enabling the selective degradation of specific proteins within cells. Its application is significant in drug discovery and therapeutic research, especially for diseases where traditional small-molecule inhibitors are ineffective. By facilitating the removal of disease-causing proteins, it offers a novel approach to treating conditions such as cancer, neurodegenerative disorders, and other protein-driven pathologies. Additionally, it aids in studying protein function and cellular pathways, contributing to advancements in molecular biology and pharmacology.